Clinical Trials Register

Summary
EudraCT Number:	2006-004457-20
Sponsor's Protocol Code Number:	P051071
National Competent Authority:	France - ANSM
Clinical Trial Type:	EEA CTA
Trial Status:	Ongoing
Date on which this record was first entered in the EudraCT database:	2008-03-25
Trial results

Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL

Expand All Collapse All

A. Protocol Information

A.1

Member State Concerned

France - ANSM

A.2

EudraCT number

2006-004457-20

A.3

Full title of the trial

Evaluation de l'action neuroréparatrice fonctionnelle et morphologique du traitement antidepresseur au cours de la rémission clinique dans la dépression recurrente.

A.3.2

Name or abbreviated title of the trial where available

RESILIENCE

A.4.1

Sponsor's protocol code number

P051071

A.7

Trial is part of a Paediatric Investigation Plan

Information not present in EudraCT

A.8

EMA Decision number of Paediatric Investigation Plan

B. Sponsor Information
B.Sponsor: 1
B.1.1	Name of Sponsor	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
B.1.3.4	Country	France
B.3.1 and B.3.2	Status of the sponsor	Non-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1	Name of organisation providing support
B.4.2	Country
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1	Name of organisation
B.5.2	Functional name of contact point

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.1.1	Trade name	Stablon
D.2.1.1.2	Name of the Marketing Authorisation holder	Servier
D.2.1.2	Country which granted the Marketing Authorisation	France
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	Stablon
D.3.2	Product code	Stablon
D.3.4	Pharmaceutical form	Buccal tablet
D.3.4.1	Specific paediatric formulation	Information not present in EudraCT
D.3.7	Routes of administration for this IMP	Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Tianeptine
D.3.9.1	CAS number	66981-73-5
D.3.9.3	Other descriptive name	Stablon
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	12,5 mg
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	Information not present in EudraCT
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	Information not present in EudraCT
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	Information not present in EudraCT
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	Information not present in EudraCT
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	Information not present in EudraCT
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	Information not present in EudraCT
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 2
D.1.2 and D.1.3	IMP Role	Comparator
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.1.1	Trade name	Effexor
D.2.1.1.2	Name of the Marketing Authorisation holder	Wyeth-Lederlé
D.2.1.2	Country which granted the Marketing Authorisation	France
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	Effexor
D.3.2	Product code	Effexor
D.3.4	Pharmaceutical form	Buccal tablet
D.3.4.1	Specific paediatric formulation	Information not present in EudraCT
D.3.7	Routes of administration for this IMP	Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Venlafaxine
D.3.9.1	CAS number	99300-78-4
D.3.9.3	Other descriptive name	Effexor
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	50 mg
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	Information not present in EudraCT
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	Information not present in EudraCT
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	Information not present in EudraCT
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	Information not present in EudraCT
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	Information not present in EudraCT
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	Information not present in EudraCT
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 3
D.1.2 and D.1.3	IMP Role	Comparator
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.1.1	Trade name	Norset
D.2.1.1.2	Name of the Marketing Authorisation holder	Organon
D.2.1.2	Country which granted the Marketing Authorisation	France
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	Norset
D.3.2	Product code	Norset
D.3.4	Pharmaceutical form	Buccal tablet
D.3.4.1	Specific paediatric formulation	Information not present in EudraCT
D.3.7	Routes of administration for this IMP	Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Mirtazapine
D.3.9.1	CAS number	61337-67-5
D.3.9.3	Other descriptive name	Norset
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	15
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	Information not present in EudraCT
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	Information not present in EudraCT
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	Information not present in EudraCT
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	Information not present in EudraCT
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	Information not present in EudraCT
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	Information not present in EudraCT
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1	Is a Placebo used in this Trial?	Yes
D.8.3	Pharmaceutical form of the placebo	Buccal tablet
D.8.4	Route of administration of the placebo	Buccal use

E. General Information on the Trial

E.1 Medical condition or disease under investigation

E.1.1

Medical condition(s) being investigated

Dépression récurrente

MedDRA Classification

E.1.2 Medical condition or disease under investigation

E.1.2	Version	8.1
E.1.2	Level	PT
E.1.2	Classification code	10025454
E.1.2	Term	Dépression récurrente

E.1.3

Condition being studied is a rare disease

E.2 Objective of the trial

E.2.1

Main objective of the trial

Evaluer l'impact des recurrences de la dépression au niveau des structures Hyppocampiques et des fonctions cognitives dans le trouble Dépressif majeur Récurrent (TDMR)(DSM-IV) en phase aïgu, par rapport aux sujets témoins(ST) et aux patients présentant leur premier épisode dépressif majeur (PED)

E.2.2

Secondary objectives of the trial

1- Evaluer l'impact des recurrences de la dépression sur les fonctions cognitives dans le trouble dépressif majeur récurent(DMR)(DSM-IV), d'évaluer le lien entre l'atrophie de l'hyppocampe et la resistance aux traitements antidépresseurs, d'évaluer par l'analyse IRM: le potentiel neuroréparateur d'un traitement antidépresseur de consolidation, le potentiel neuroréparateur de la tianeptine.
- 1) d'évaluer l'impact des récurrences de la dépression sur les fonctions cognitives dans le trouble dépressif majeur récurrent
2) d'évaluer le lien entre l'atrophie de l'hyppocampe etl a résistance au traitement anti-dépresseur
3) d'évaluer par l'analyse d'IRM
- le potentiel neuroréparateur d'un traitement anti-dépresseur de consolidation
- le potentiel neuroréparateur de le tianeptine

E.2.3

Trial contains a sub-study

E.3

Principal inclusion criteria

Critère d'inclusion des patients
- patients hospitalisés, n'ayant pas répondu en ambulatoire, au traitement antidépresseur
- hommes et femmes âgées de 18 à 55 ans
- patient répondant aux critères DSM-IV d'un trouble dépressif majeur récurrent, Récurrent soit d'un Trouble dépressif majeur, Episode isolée
- score à la MADRS supérieur ou égal à 20
- langue maternelle : français
- consentement éclairé et écrit du patient
- absence de comorbidité sur l'axe I et sur l'axe II du DMS IV (ex: abus d'alcool et /ou de substance tosique, état de stress post-traumatique, etc.)
- absence d'affection somatiques susceptibles d'affecter les capacités cognitives et les structurtes cérébrales (infection par VIH, SEP, Lupus, maladie de parkinson, épilepsie, démences, endocrtinopathie, etc...)

- Critères d'inclusion des sujets témoins
- sujets indemnes de troubles mentaux sur l'axe 1 et 2 du DSM-IV après évaluation par l'entretien clinique (critère de la DSP) et par l'entretien structuré ( le MINI)
- consentement éclairé et écrit du sujet
- âge compris entre 18 et 55 ans

E.4

Principal exclusion criteria

Patients
- score supérieur ou égal à 2 à l'item "idées suicidaires" de la MADRS
- contre-indication à la réalisation d'une IRM (...), une évaluation de la faisabilité de l'IRM sera systématiquement effectuée avant l'examen
- malades hospitalisés sous contrainte selon les termes de la loi du 27 juin 1990 (hospitalisation sur le demande d'un tiers ou hospitalisation d'office)
- antécédents ou indication actuelle de traitement par électroconvulsivothérapie (ECT) qui est susceptible d'induire des troubles mnésiques pour la deuxième partie de l'étude;
- antécédent de traitement par thymorégulateur (sels du lithium, vaproate, tegrétol) dans les 5 ans ayant précédé l'inclusion
- potentialisation récente par le extraits thyroïens (Cynomel, DCI? liothyronine sodique; cp 25microg) dans les 6 mois qui ont précédé l'inclusion
- grossesse
- contre indication à l'utilisation de IRSNA + NASSA
- non affiliation à un régime de sécurité sociale (bénéficiéire ou ayant droit).

Témoins
- contre indication à la réalisation de l'examen IRM
- affections médicales susceptibles d'affecter les capacités cognitives et les structurtes cérébrales (infection par VIH, SEP, Lupus, maladie de parkinson, épilepsie, démences, etc...)
- non affiliation à un régime de sécurité sociale (bénéficiaire ou ayant droit)
- grossesse

E.5 End points

E.5.1

Primary end point(s)

Principal: volume de l'hippocampe mesuré par l'IRM (technique VBM), qui sera comparé à l'inclusion entre deux groupes de patients: patient TDMR et le groupe composé de ST et PED. Variables mesurées et méthodologie: les variables d'IRM caractérisant la densité en substance grise et le volume de l'hippocampe.

Secondaires
-variables cliniques et psychopathologiques: scores aux échelles (MADRS, HAD, EGF, CGI).
La réponse au traitement anti-dépresseur au cours d'un épisode dépressif majeur a été définie par une baisse > ou = à 50% du score à l'échelle MADRS.
Les indices cliniques ont été évalués par le MINI et l'entretien clinique ainsi que par le recueil des informations auprès des médecins traitants et l'étude du dossier médical , ces variables étaient l'âge, le sexe, le nombre d'épisodes dépressifs, l'âge des début des troubles, le nombre d'hospitalisation, la durée de l'épisode actue, la durée de la maladie, les caractéristique symptomatiques de l'épisode dépressif actuel.

-variables cognitives: scores de tests (questionnaires)
Chaque épreuve cognitive a donné lieu à un ensemble de sous-scores qui ont été ajustés selon les normes d chaque tests tenant compte de l'âge des sujets et du niveau socio-éducatif.

E.6 and E.7 Scope of the trial

E.6

Scope of the trial

E.6.1

Diagnosis

E.6.2

Prophylaxis

E.6.3

Therapy

Yes

E.6.4

Safety

E.6.5

Efficacy

Yes

E.6.6

Pharmacokinetic

E.6.7

Pharmacodynamic

E.6.8

Bioequivalence

E.6.9

Dose response

E.6.10

Pharmacogenetic

E.6.11

Pharmacogenomic

E.6.12

Pharmacoeconomic

E.6.13

Others

Yes

E.6.13.1

Other scope of the trial description

Impact anatomo-clinique des récurrences dépressives.

E.7

Trial type and phase

E.7.1

Human pharmacology (Phase I)

E.7.1.1

First administration to humans

E.7.1.2

Bioequivalence study

E.7.1.3

Other

Yes

E.7.1.3.1

Other trial type description

Impact du traitement au niveau de l'hippocampe

E.7.2

Therapeutic exploratory (Phase II)

E.7.3

Therapeutic confirmatory (Phase III)

E.7.4

Therapeutic use (Phase IV)

Yes

E.8 Design of the trial

E.8.1

Controlled

Yes

E.8.1.1

Randomised

Yes

E.8.1.2

Open

E.8.1.3

Single blind

E.8.1.4

Double blind

Yes

E.8.1.5

Parallel group

Yes

E.8.1.6

Cross over

E.8.1.7

Other

E.8.2

Comparator of controlled trial

E.8.2.1

Other medicinal product(s)

E.8.2.2

Placebo

Yes

E.8.2.3

Other

E.8.3

The trial involves single site in the Member State concerned

E.8.4

The trial involves multiple sites in the Member State concerned

Yes

E.8.4.1

Number of sites anticipated in Member State concerned

E.8.5

The trial involves multiple Member States

E.8.6 Trial involving sites outside the EEA

E.8.6.1

Trial being conducted both within and outside the EEA

E.8.6.2

Trial being conducted completely outside of the EEA

Information not present in EudraCT

E.8.7

Trial has a data monitoring committee

E.8.8

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial

E.8.9 Initial estimate of the duration of the trial

E.8.9.1

In the Member State concerned years

E.8.9.1

In the Member State concerned months

E.8.9.1

In the Member State concerned days

F. Population of Trial Subjects

F.1 Age Range

F.1.1

Trial has subjects under 18

F.1.1.1

In Utero

F.1.1.2

Preterm newborn infants (up to gestational age < 37 weeks)

F.1.1.3

Newborns (0-27 days)

F.1.1.4

Infants and toddlers (28 days-23 months)

F.1.1.5

Children (2-11years)

F.1.1.6

Adolescents (12-17 years)

F.1.2

Adults (18-64 years)

Yes

F.1.3

Elderly (>=65 years)

F.2 Gender

F.2.1

Female

Yes

F.2.2

Male

Yes

F.3 Group of trial subjects

F.3.1

Healthy volunteers

Yes

F.3.2

Patients

Yes

F.3.3

Specific vulnerable populations

Yes

F.3.3.1

Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2008-03-25.

Yes

F.3.3.2

Women of child-bearing potential using contraception

Yes

F.3.3.3

Pregnant women

F.3.3.4

Nursing women

F.3.3.5

Emergency situation

F.3.3.6

Subjects incapable of giving consent personally

F.3.3.7

Others

Yes

F.3.3.7.1

Details of other specific vulnerable populations

Adultes (18-55 ans)

F.4 Planned number of subjects to be included

F.4.1

In the member state

G. Investigator Networks to be involved in the Trial

N. Review by the Competent Authority or Ethics Committee in the country concerned

Competent Authority Decision

Authorised

Date of Competent Authority Decision

2008-07-04

Ethics Committee Opinion of the trial application

Favourable

Ethics Committee Opinion: Reason(s) for unfavourable opinion

Date of Ethics Committee Opinion

2008-06-18

P. End of Trial
P.	End of Trial Status	Ongoing

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials